This definition appears very rarely
and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
Samples in periodicals archive:
Motesanib is an investigational, orally administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptors, and stem cell factor receptor.
Academy professor Kari Alitalo and co-workers at the University of Helsinki, Finland, have previously shown that antibodies directed towards vascular endothelial growth factor receptor (VEGFR)-3 can inhibit lymphatic metastasis by 50-70 percent in pre-clinical tumor models.
Identification and Characterization of Novel Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor 2 [Abstract # 1439] Inhibition of the vascular endothelial growth factor receptor signaling pathway with antibodies or small molecules has been proven effective as an anti-cancer therapy.
Scope: - Patient-based forecasts for Exelixis's lead candidate, cabozantinib, supported by key opinion leader research - Assessment of Exelixis's corporate strategy, operating performance, and earlier-stage pipeline Highlights: Exelixis's lead candidate is cabozantinib, an oral inhibitor of the hepatocyte growth factor receptor MET, receptor tyrosine kinase RET, and the vascular endothelial growth factor receptor 2 (VEGFR2).
Angiocept is an Adnectin that was designed to be both a potent and highly specific antagonist of the vascular endothelial growth factor receptor 2 (VEGFR-2).
Enrollment Underway for a Pivotal Phase III Study of ZACTIMA (ZD6474) in Advanced Non-small-cell Lung Cancer ATLANTA, June 4 /PRNewswire-FirstCall/ -- AstraZeneca announced today the results of two Phase II studies, Trial 003 and 006, with ZACTIMA (ZD6474), a compound which targets both epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGF) cell signaling pathways.
ZD6474 is a potent once daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR) signalling that has additional activity against epidermal growth factor receptor (EGFR) signalling.
CT-322 is an Adnectin that was designed to be both a potent and highly specific antagonist of the vascular endothelial growth factor receptor 2 (VEGFR-2).